Trine Svejborg Holmvang
Chief Operating Officer
Trine Svejborg Holmvang joined MC2 Therapeutics in 2022, bringing more than 25 years of expertise in project and alliance management of development programs within biotech and the pharmaceutical industry. Prior to joining MC2 Therapeutics, Trine held a series of senior positions at Bavarian Nordic A/S, where she was responsible for overseeing strategic vaccine development initiatives of international significance including supply to the U.S. Strategic National Stockpile, while managing and cultivating high-value strategic alliances with international partners. Trine holds a Master of Science in Pharmaceutical Science from the University of Copenhagen.